U.S. District Judge Karen Marston of Philadelphia recently issued a pivotal ruling in a closely watched multidistrict litigation (MDL) involving diabetes and weight-loss drugs.
The litigation focuses on alleged side effects of medications such as Ozempic, Wegovy, and Mounjaro, developed by Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY).
Also Read: Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
The ruling centers on the defendants’ request to address several key legal questions at the outset of the case, which could potentially streamline or even halt the litigation before it gains momentum.
Reuters ...
